A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

This study is testing zimberelimab — an immune checkpoint inhibitor — combined with standard AVD chemotherapy (doxorubicin, vinblastine, dacarbazine) as a first-line treatment for early-stage classical Hodgkin lymphoma. **You may be eligible if...** - You have a new diagnosis of classical Hodgkin lymphoma confirmed by tissue testing - Your disease is Stage I or II - You are between 18 and 45 years old, OR over 60 years old and unable to tolerate standard chemotherapy - You have at least one measurable tumor - Your general health is adequate (ECOG status 0–3) - You are expected to survive at least 3 months **You may NOT be eligible if...** - You have nodular lymphocyte-predominant Hodgkin lymphoma (a different subtype) - You are planned for a stem cell transplant - Your lymphoma has spread to the brain or spinal fluid - You have contraindications to radiation or immune checkpoint therapy Talk to your doctor to see if this trial is right for you.